New study examines risks and benefits of the first line treatment for diabetes

Although the drug metformin is considered the gold standard in the management of type 2 diabetes, a study by a group of French researchers published in this week's PLoS Medicine suggests that the long-term benefits of this drug compared with the risks are not clearly established—an important finding given that currently, thousands of people around the world are regularly taking metformin to help control their blood sugar levels in the belief that it also has long-lasting health benefits.

For the past 14 years, has been recommended as the first-line treatment for type 2 after a landmark study (the UK Prospective Diabetes Study) reported that when combined with dietary control measures, metformin reduced death from all causes in overweight people with type 2 diabetes. However, an overlooked finding from this study was that in non-overweight people with type 2 diabetes, metformin may actually increase the risk of death.

In this new analysis, the authors led by Catherine Cornu from the Clinical Investigation Centre, in Lyon, France, analysed the data available from all relevant studies to re-evaluate the balance of the benefits versus the risks of taking metformin for .

Using information from 13 randomized controlled trials (which included a total of more than 13,000 patients) the authors found that compared to other drugs, metformin had no effect on the risk of death from all causes or on the risk of death from cardiovascular disease. Furthermore, metformin had no significant effect on the risk of developing cardiovascular conditions such as heart attacks, strokes, and heart failure.

The authors conclude: "We cannot exclude beyond any reasonable doubt that metformin use increases or decreases the risk of all-cause mortality or cardiovascular mortality."

They explain: "The specific efficacy of metformin to prevent death or cardiovascular events has not been proven by current studies. The number and quality of available studies are insufficient."

The authors recommend: "Further studies are needed to clarify this problematic situation. Metformin may not be the best comparator [drug] for evaluating new hypoglycaemic [blood sugar-lowering] drugs. However, it is not clear which comparator [drug] has the most favourable risk/benefit ratio."

It is essential that patients taking metformin who have any concerns do not stop the without consulting their doctor, especially as the authors conclude that "Compared with other antidiabetic treatments, metformin may be the one with the least disadvantages. It does not induce hypoglycaemia, weight gain, and heart failure. It is also associated with a reduced rate of mortality among patients with atherothrombosis."

More information: Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, et al. (2012) Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. PLoS Med 9(4): e1001204. doi:10.1371/journal.pmed.1001204

add to favorites email to friend print save as pdf

Related Stories

Diabetes drug can prevent heart disease

Mar 26, 2012

The widely used diabetes medicine metformin can have protective effects on the heart, reveals a new study conducted at the Sahlgrenska Academy, at the University of Gothenburg, Sweden.

Recommended for you

Diabetes and Thanksgiving can live in harmony

Nov 25, 2014

As you may know, November is National Diabetes Month. If you, a loved one, or a Thanksgiving guest have diabetes or prediabetes, this column is dedicated to you, as you may be wondering how to enjoy one of the most food-laden ...

Does a yogurt a day keep diabetes away?

Nov 24, 2014

A high intake of yogurt has been found to be associated with a lower risk of developing type 2 diabetes, according to research published in open access journal BMC Medicine. This highlights the importance of hav ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.